Coherus BioSciences Analyst Ratings
Coherus BioSciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/28/2023 | 501.5% | Truist Securities | → $12 | Reiterates | Buy → Buy |
11/17/2023 | 451.38% | Baird | → $11 | Initiates Coverage On | → Outperform |
11/08/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
11/07/2023 | 551.63% | HC Wainwright & Co. | $20 → $13 | Maintains | Buy |
10/23/2023 | 250.88% | Barclays | $8 → $7 | Maintains | Overweight |
09/26/2023 | 902.51% | Truist Securities | → $20 | Reiterates | Buy → Buy |
09/26/2023 | 902.51% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
08/03/2023 | 902.51% | HC Wainwright & Co. | $24 → $20 | Maintains | Buy |
07/24/2023 | 501.5% | Citigroup | → $12 | Initiates Coverage On | → Buy |
07/14/2023 | 902.51% | Truist Securities | $22 → $20 | Maintains | Buy |
06/28/2023 | 1002.76% | Truist Securities | → $22 | Reiterates | Buy → Buy |
06/20/2023 | 1002.76% | Truist Securities | $24 → $22 | Maintains | Buy |
06/20/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
06/15/2023 | 1103.01% | Truist Securities | → $24 | Reiterates | Buy → Buy |
06/06/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
06/01/2023 | 1103.01% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
05/23/2023 | 301% | Barclays | $13 → $8 | Maintains | Overweight |
05/09/2023 | 1103.01% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
05/01/2023 | 1103.01% | Truist Securities | → $24 | Initiates Coverage On | → Buy |
03/28/2023 | 451.38% | UBS | → $11 | Upgrades | Neutral → Buy |
03/08/2023 | 551.63% | Barclays | $15 → $13 | Maintains | Overweight |
03/07/2023 | 1203.26% | HC Wainwright & Co. | $30 → $26 | Maintains | Buy |
11/16/2022 | 952.63% | Mizuho | $28 → $21 | Maintains | Buy |
11/14/2022 | 451.38% | JP Morgan | $13 → $11 | Maintains | Neutral |
08/16/2022 | 1303.51% | Mizuho | $25 → $28 | Maintains | Buy |
06/14/2022 | 250.88% | UBS | → $7 | Initiates Coverage On | → Neutral |
05/20/2022 | 1153.13% | Mizuho | $30 → $25 | Maintains | Buy |
05/09/2022 | 651.88% | Barclays | $20 → $15 | Maintains | Overweight |
03/07/2022 | 651.88% | JP Morgan | → $15 | Downgrades | Overweight → Neutral |
11/09/2021 | 1403.76% | HC Wainwright & Co. | $36 → $30 | Maintains | Buy |
07/23/2021 | 1704.51% | HC Wainwright & Co. | $26 → $36 | Maintains | Buy |
05/17/2021 | 1103.01% | Barclays | $28 → $24 | Maintains | Overweight |
05/07/2021 | 1203.26% | HC Wainwright & Co. | $29 → $26 | Maintains | Buy |
02/25/2021 | 1353.63% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
11/19/2020 | 1403.76% | Mizuho | $35 → $30 | Maintains | Buy |
11/06/2020 | 1504.01% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
08/10/2020 | 1403.76% | Truist Securities | $26 → $30 | Maintains | Buy |
08/07/2020 | 1554.14% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
07/16/2020 | 902.51% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
04/17/2020 | 1203.26% | SunTrust Robinson Humphrey | → $26 | Initiates Coverage On | → Buy |
02/28/2020 | 1403.76% | HC Wainwright & Co. | $29 → $30 | Reiterates | → Buy |
02/06/2020 | 1654.39% | JP Morgan | $33 → $35 | Maintains | Overweight |
11/07/2019 | 1453.88% | Citigroup | $27 → $31 | Maintains | Buy |
08/13/2019 | 2055.39% | Mizuho | → $43 | Initiates Coverage On | → Buy |
06/11/2019 | 1403.76% | Barclays | → $30 | Initiates Coverage On | → Overweight |
05/07/2019 | 1303.51% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/28/2023 | 501.5% | Truist 证券 | → 12 美元 | 重申 | 购买 → 购买 |
11/17/2023 | 451.38% | 贝尔德 | → 11 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
11/08/2023 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
11/07/2023 | 551.63% | HC Wainwright & Co. | 20 美元 → 13 美元 | 维护 | 买 |
2023 年 10 月 23 日 | 250.88% | 巴克莱 | 8 美元 → 7 美元 | 维护 | 超重 |
09/26/2023 | 902.51% | Truist 证券 | → 20 美元 | 重申 | 购买 → 购买 |
09/26/2023 | 902.51% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
08/03/2023 | 902.51% | HC Wainwright & Co. | 24 美元 → 20 美元 | 维护 | 买 |
2023 年 7 月 24 日 | 501.5% | 花旗集团 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
07/14/2023 | 902.51% | Truist 证券 | 22 美元 → 20 美元 | 维护 | 买 |
06/28/2023 | 1002.76% | Truist 证券 | → 22 美元 | 重申 | 购买 → 购买 |
06/20/2023 | 1002.76% | Truist 证券 | 24 美元 → 22 美元 | 维护 | 买 |
06/20/2023 | 1103.01% | HC Wainwright & Co. | → 24 美元 | 重申 | 购买 → 购买 |
06/15/2023 | 1103.01% | Truist 证券 | → 24 美元 | 重申 | 购买 → 购买 |
06/06/2023 | 1103.01% | HC Wainwright & Co. | → 24 美元 | 重申 | → 购买 |
06/01/2023 | 1103.01% | HC Wainwright & Co. | → 24 美元 | 重申 | 购买 → 购买 |
05/23/2023 | 301% | 巴克莱 | 13 美元 → 8 美元 | 维护 | 超重 |
05/09/2023 | 1103.01% | HC Wainwright & Co. | 26 美元 → 24 美元 | 维护 | 买 |
05/01/2023 | 1103.01% | Truist 证券 | → 24 美元 | 启动覆盖范围开启 | → 购买 |
03/28/2023 | 451.38% | 瑞银(UBS) | → 11 美元 | 升级 | 中性 → 买入 |
03/08/2023 | 551.63% | 巴克莱 | 15 美元 → 13 美元 | 维护 | 超重 |
03/07/2023 | 1203.26% | HC Wainwright & Co. | 30 美元 → 26 美元 | 维护 | 买 |
11/16/2022 | 952.63% | 瑞穗市 | 28 美元 → 21 美元 | 维护 | 买 |
11/14/2022 | 451.38% | 摩根大通 | 13 美元 → 11 美元 | 维护 | 中立 |
08/16/2022 | 1303.51% | 瑞穗市 | 25 美元 → 28 美元 | 维护 | 买 |
06/14/2022 | 250.88% | 瑞银(UBS) | → 7 美元 | 启动覆盖范围开启 | → 中立 |
05/20/2022 | 1153.13% | 瑞穗市 | 30 美元 → 25 美元 | 维护 | 买 |
05/09/2022 | 651.88% | 巴克莱 | 20 美元 → 15 美元 | 维护 | 超重 |
03/07/2022 | 651.88% | 摩根大通 | → 15 美元 | 降级 | 超重 → 中性 |
2021 年 9 月 11 日 | 1403.76% | HC Wainwright & Co. | 36 美元 → 30 美元 | 维护 | 买 |
2021 年 7 月 23 日 | 1704.51% | HC Wainwright & Co. | 26 美元 → 36 美元 | 维护 | 买 |
05/17/2021 | 1103.01% | 巴克莱 | 28 美元 → 24 美元 | 维护 | 超重 |
05/07/2021 | 1203.26% | HC Wainwright & Co. | 29 美元 → 26 美元 | 维护 | 买 |
2021 年 2 月 25 日 | 1353.63% | HC Wainwright & Co. | 33 美元 → 29 美元 | 维护 | 买 |
2020 年 11 月 19 日 | 1403.76% | 瑞穗市 | 35 美元 → 30 美元 | 维护 | 买 |
11/06/2020 | 1504.01% | HC Wainwright & Co. | 33 美元 → 32 美元 | 维护 | 买 |
08/10/2020 | 1403.76% | Truist 证券 | 26 美元 → 30 美元 | 维护 | 买 |
08/07/2020 | 1554.14% | HC Wainwright & Co. | 30 美元 → 33 美元 | 维护 | 买 |
2020 年 7 月 16 日 | 902.51% | B of A 类证券 | → 20 美元 | 启动覆盖范围开启 | → 中立 |
2020 年 4 月 17 日 | 1203.26% | SunTrust 罗宾逊·汉弗莱 | → 26 美元 | 启动覆盖范围开启 | → 购买 |
2020 年 2 月 28 日 | 1403.76% | HC Wainwright & Co. | 29 美元 → 30 美元 | 重申 | → 购买 |
02/06/2020 | 1654.39% | 摩根大通 | 33 美元 → 35 美元 | 维护 | 超重 |
11/07/2019 | 1453.88% | 花旗集团 | 27 美元 → 31 美元 | 维护 | 买 |
08/13/2019 | 2055.39% | 瑞穗市 | → 43 美元 | 启动覆盖范围开启 | → 购买 |
2019 年 11 月 6 日 | 1403.76% | 巴克莱 | → 30 美元 | 启动覆盖范围开启 | → 超重 |
05/07/2019 | 1303.51% | HC Wainwright & Co. | → 28 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Coherus BioSciences (CHRS)?
Coherus BioSciences(CHRS)的目标价格是多少?
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Truist Securities on November 28, 2023. The analyst firm set a price target for $12.00 expecting CHRS to rise to within 12 months (a possible 501.50% upside). 22 analyst firms have reported ratings in the last year.
Truist Securities于2023年11月28日公布了Coherus BioSciences(纳斯达克股票代码:CHRS)的最新目标股价。该分析公司将目标股价定为12.00美元,预计CHRS将在12个月内升至12个月内(可能上涨501.50%)。22家分析公司去年公布了评级。
What is the most recent analyst rating for Coherus BioSciences (CHRS)?
Coherus BioSciences(CHRS)的最新分析师评级是多少?
The latest analyst rating for Coherus BioSciences (NASDAQ: CHRS) was provided by Truist Securities, and Coherus BioSciences reiterated their buy rating.
Truist Securities提供了Coherus BioSciences(纳斯达克股票代码:CHRS)的最新分析师评级,Coherus BioSciences重申了其买入评级。
When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?
Coherus BioSciences(CHRS)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Coherus BioSciences的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Coherus BioSciences的最新评级是在2023年11月28日公布的,因此您应该预计下一个评级将在2024年11月28日左右公布。
Is the Analyst Rating Coherus BioSciences (CHRS) correct?
分析师对 Coherus BioSciences (CHRS) 的评级正确吗?
While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Coherus BioSciences (CHRS) is trading at is $2.00, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Coherus BioSciences(CHRS)评级得到了重申,目标股价为0.00美元至12.00美元。Coherus BioSciences(CHRS)目前的交易价格为2.00美元,在分析师的预测区间内。